Anna Streltsova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Streltsova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Angela Tsvetkova
Translational Medicine Research Center, Sirius University of Science and Technology, 354340 Sochi, Russia
1 shared publication - Dmitriy Ovcharenko
Altogen Labs, 11200 Menchaca Road, Austin, TX 78748, USA
1 shared publication - Igor Shalik
Translational Medicine Research Center, Sirius University of Science and Technology, 354340 Sochi, Russia
1 shared publication - Maksim V. Baranov
Biotechnology Department, Sirius University of Science and Technology, 354349 Sirius, Russia
1 shared publication - Roman Alekseyevich Ivanov
Translational Medicine Research Center, Sirius University of Science and Technology, 1 Olympic Avenue, 354340 Sochi, Russia
1 shared publication - Vasiliy Reshetnikov
Translational Medicine Research Center, Sirius University of Science and Technology, 354340 Sochi, Russia
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 843
RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation
Multiple myeloma (MM) is a challenging hematologic malignancy characterized by clonal plasma cell proliferation, often leading to significant morbidity and mortality worldwide. Despite advances in chemotherapy and CAR-T therapies, MM remains incurable due to tumor heterogeneity, immune evasion, and microenvironment remodeling—exacerbated by toxicities like cytokine release syndrome and myelosuppression. This urgent unmet need demands innovative strategies. In this review, we assess cutting-edge RNA-based therapeutics for MM modulation, drawing on preclinical and clinical evidence on modalities including mRNA vaccines, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA (miRNA) mimics/inhibitors. We further explore RNA-engineered cell therapies, such as transient CAR-T platforms and lipid nanoparticle-delivered systems targeting the bone marrow niche. By integrating these insights, we underscore RNA technologies’ transformative potential to achieve durable remissions, overcome resistance, and reduce costs—paving the way for personalized, safer treatments in refractory MM.
- 14 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 843
Open AccessRNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation
Multiple myeloma (MM) is a challenging hematologic malignancy characterized by clonal plasma cell proliferation, often leading to significant morbidity and mortality worldwide. Despite advances in chemotherapy and CAR-T therapies, MM remains incurable due to tumor heterogeneity, immune evasion, and microenvironment remodeling—exacerbated by toxicities like cytokine release syndrome and myelosuppression. This urgent unmet need demands innovative strategies. In this review, we assess cutting-edge RNA-based therapeutics for MM modulation, drawing on preclinical and clinical evidence on modalities including mRNA vaccines, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA (miRNA) mimics/inhibitors. We further explore RNA-engineered cell therapies, such as transient CAR-T platforms and lipid nanoparticle-delivered systems targeting the bone marrow niche. By integrating these insights, we underscore RNA technologies’ transformative potential to achieve durable remissions, overcome resistance, and reduce costs—paving the way for personalized, safer treatments in refractory MM.